BioAge Stock Rallies 29% Following Upsized $198M IPO
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Eli Lilly Unusual Options Activity
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Novo Nordisk, Lilly Weight Loss Drugs Poised for Price Reductions: Cantor's Louise Chen
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Amgen Analyst Ratings
Lilly Ebglyss Demonstrates Durable Disease Control in Atopic Dermatitis
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
US stocks closed: S&P, Dow hit new highs again. Chinese concept stocks staged a 'Golden Dragon Soaring'.
1. The three major indices collectively rose, with the S&P 500 index and the Dow hitting new highs; 2. Chinese concept stocks generally soared, with the Nasdaq Golden Dragon Index in China rising by 9.13%; 3. Nvidia rose by about 4%, temporarily halting the selloff by Huang Renxun; 4. The US Department of Justice sued Visa, accusing it of illegal monopolization.